Chimerix, Inc. Issues Statement Thanking The FDA For Collaboration In Developing Protocol To Treat Patients With Life-Threatening Adenovirus Infection

DURHAM, N.C., March 14, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX) today issued a statement thanking the U.S. Food and Drug Administration (FDA) for its collaboration in developing a protocol for the immediate initiation of a 20-patient pilot trial of open-label brincidofovir for the treatment of adenovirus infections in immunocompromised patients.

Help employers find you! Check out all the jobs and post your resume.